Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Accured Expenses (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Change in Accured Expenses for 10 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 79.65% year-over-year to $1.1 million, compared with a TTM value of -$7.5 million through Sep 2025, down 185.78%, and an annual FY2024 reading of $11.2 million, up 562.21% over the prior year.
  • Change in Accured Expenses was $1.1 million for Q3 2025 at Spero Therapeutics, up from -$1.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.3 million in Q3 2024 and bottomed at -$9.5 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is -$233263.2, with a median of -$6000.0 recorded in 2023.
  • Peak annual rise in Change in Accured Expenses hit 40033.33% in 2024, while the deepest fall reached 960.36% in 2024.
  • Year by year, Change in Accured Expenses stood at $5.3 million in 2021, then crashed by 83.38% to $880000.0 in 2022, then tumbled by 100.68% to -$6000.0 in 2023, then skyrocketed by 40033.33% to $2.4 million in 2024, then plummeted by 54.84% to $1.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for SPRO at $1.1 million in Q3 2025, -$1.5 million in Q2 2025, and -$9.5 million in Q1 2025.